Greenwich LifeSciences, Inc.: updates and filings

GLSINASDAQHealthcare · Pharmaceutical Preparations

Price

$19.25

November 20, 2026Market cap $283M

What Ploutos Investor adds for Greenwich LifeSciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has risen 40% since Nov 16, 2026, when the 10-Q these figures come from was filed ($13.76 then, $19.25 on Nov 20, 2026). The figures date from before that move.10-Q
  • The filings show substantial debt that is not stated in a form we can read. The debt, net cash, enterprise value, the multiples built on it and the return on invested capital would leave that debt out, so we leave them out.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Jun 1, 2026 latest annualNov 16, 2026 latest quarterly
  • Nov 16, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Oct 26, 2026Additional annual meeting material
    FormDEFA14A
  • Oct 26, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Oct 26, 2026Annual meeting proxy statement
    FormDEF 14A
  • Aug 11, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Jun 4, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • Jun 1, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Mar 31, 2026Notice that the annual report will be filed late
    FormNT 10-K
  • Dec 18, 2025Shareholder vote
    Form8-K
  • Nov 14, 2025Quarterly reportfor the period to Sep 30, 2025
    Form10-Q
  • Nov 3, 2025Annual report to shareholdersfor the period to Dec 31, 2024
    FormARS
  • Nov 3, 2025Additional annual meeting material
    FormDEFA14A
  • Nov 3, 2025Annual meeting proxy statement
    FormDEF 14A
  • Aug 14, 2025Quarterly reportfor the period to Jun 30, 2025
    Form10-Q
  • Jul 24, 2025Change of auditor
    Form8-K
  • May 20, 2025Quarterly reportfor the period to Mar 31, 2025
    Form10-Q
  • May 15, 2025Notice that the quarterly report will be filed late
    FormNT 10-Q
  • Apr 15, 2025Annual reportfor the period to Dec 31, 2024
    Form10-K
  • Mar 31, 2025Notice that the annual report will be filed late
    FormNT 10-K
  • Dec 20, 2024Shares registered for employees
    FormS-8
  • Dec 19, 2024Shareholder vote
    Form8-K
  • Nov 14, 2024Quarterly reportfor the period to Sep 30, 2024
    Form10-Q
  • Nov 1, 2024Additional annual meeting material
    FormDEFA14A
  • Nov 1, 2024Annual report to shareholdersfor the period to Dec 31, 2023
    FormARS
  • Nov 1, 2024Annual meeting proxy statement
    FormDEF 14A

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jan 27, 2020.

The full analysis

What do Greenwich LifeSciences's filings show?

The filings are where every one of Greenwich LifeSciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.